Full Text:
<51>
CLC number:
On-line Access: 2024-12-30
Received: 2024-07-23
Revision Accepted: 2024-11-11
Crosschecked: 0000-00-00
Cited: 0
Clicked: 90
New character of cancer immunotherapy: trends in viral tumor immunotherapy with influenza virus-based approaches
| |||||||||||||
Shiyao HU, Yiqi CAI, Yong SHEN, Yingkuan SHAO, Yushen DU, Yiding CHEN. New character of cancer immunotherapy: trends in viral tumor immunotherapy with influenza virus-based approaches[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .
@article{title="New character of cancer immunotherapy: trends in viral tumor immunotherapy with influenza virus-based approaches",
author="Shiyao HU, Yiqi CAI, Yong SHEN, Yingkuan SHAO, Yushen DU, Yiding CHEN",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2400381"
}
%0 Journal Article
%T New character of cancer immunotherapy: trends in viral tumor immunotherapy with influenza virus-based approaches
%A Shiyao HU
%A Yiqi CAI
%A Yong SHEN
%A Yingkuan SHAO
%A Yushen DU
%A Yiding CHEN
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2400381
TY - JOUR
T1 - New character of cancer immunotherapy: trends in viral tumor immunotherapy with influenza virus-based approaches
A1 - Shiyao HU
A1 - Yiqi CAI
A1 - Yong SHEN
A1 - Yingkuan SHAO
A1 - Yushen DU
A1 - Yiding CHEN
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2400381
Abstract: Immunomodulatory cancer therapy is witnessing the rise of viral immunotherapy. The oncolytic influenza A virus, although promising in preclinical investigations, still remains to be implemented in clinical practice. Recent progress in genetic engineering, coupled with experiential insights, offers opportunities to enhance the therapeutic efficacy of the influenza A virus. This review explores the use of the influenza virus, its attenuated forms, and associated vaccines in cancer immunotherapy, highlighting their respective advantages and challenges. We further elucidate methods for engineering influenza viruses and innovative approaches to augment them with cytokines or immune checkpoint inhibitors, aiming to maximize their clinical impact. Our goal is to provide insights essential for refining influenza A virus-based viral tumor immunotherapies.
Open peer comments: Debate/Discuss/Question/Opinion
<1>